Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

被引：12

作者：

Kasi, Pashtoon Murtaza ^{[1
]}

Aushev, Vasily N. ^{[2
]}

Ensor, Joe ^{[2
]}

Langer, Nathan ^{[3
]}

Wang, Christopher Gene ^{[4
]}

Cannon, Timothy Lewis ^{[5
]}

Berim, Lyudmyla Derby ^{[6
]}

Feinstein, Trevor ^{[7
]}

Grothey, Axel ^{[8
]}

McCollom, Joseph William ^{[9
]}

Kalmadi, Sujith R. ^{[10
]}

Zakari, Ahmed ^{[11
]}

Dayyani, Farshid ^{[12
]}

Gravenor, Donald ^{[13
]}

Meyer, Janelle Marie ^{[14
]}

Sharif, Saima ^{[15
]}

Jurdi, Adham A. ^{[2
]}

Liu, Minetta C. ^{[2
]}

Aleshin, Alexey ^{[2
]}

Kopetz, Scott ^{[16
]}

机构：

[1] NewYork Presbyterian Hosp, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA

[2] Natera Inc, Austin, TX USA

[3] Virginia Canc Inst QCCA, Richmond, VA USA

[4] Alabama Oncol, Birmingham, AL USA

[5] Inova Schar Canc Inst, Fairfax, VA USA

[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[7] Piedmont Canc Inst, Atlanta, GA USA

[8] West Canc Ctr, Germantown, TN USA

[9] Parkview Canc Inst, Ft Wayne, IN USA

[10] Ironwood Canc & Res Ctr, Chandler, AZ USA

[11] Adventhlth Canc Inst, Orlando, FL USA

[12] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA USA

[13] Baptist Canc Ctr, Memphis, TN USA

[14] Oregon Oncol Specialists, Salem, OR USA

[15] Univ Iowa, Iowa City, IA USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-237-255; 281-206-4760-6705; 261-376-454; 281-318-9508; 281-318-9493; 261-492-3532-2370-7650-2454; 261-376; 9; 7; 6; 4; 2;

D O I：

10.1200/JCO.2024.42.3_suppl.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9 / 9

页数：1

共 50 条

[1] Combine high risk factors with circulating tumor DNA (ctDNA) to assist adjuvant chemotherapy ( ACT) decision in Stage II colorectal cancer (CRC)
Yuan, Xie Gui
Miao, Liu
Li, Huang Meng
CANCER RESEARCH, 2022, 82 (12)
[2] Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.
Shah, Purvi K.
Aushev, Vasily N.
Ensor, Joe
Sanchez, Stephanie A.
Wang, Christopher Gene
Cannon, Timothy Lewis
Berim, Lyudmyla Derby
Feinstein, Trevor
Grothey, Axel
McCollom, Joseph William
Kalmadi, Sujith R.
Zakari, Ahmed
Dayyani, Farshid
Gravenor, Don
Liu, Minetta C.
Jurdi, Adham A.
Aleshin, Alexey
Meyer, Janelle Marie
Sharif, Saima
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 15 - 15
[3] Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).
Diehn, Maximilian
Alizadeh, Ash A.
Adams, Hans-Peter
Lee, John J.
Klassen, Susanne
Palma, John F.
Hinzman, Bernd
Lovejoy, Alexander F.
Newman, Aaron M.
Yao, Lijing
Yaung, Stephanie
Balasubramanyam, Aarthi
Rohr, Ulrich Peter
Rosenthal, Andre
Kube, Rainer
Steinmueller, Thomas
Marusch, Frank
Mantke, Rene
Heise, Michael
Pross, Matthias
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Detection of Mutant Circulating Tumor DNA (ctDNA) in Plasma of Patients With Colorectal Cancer (CRC)
Dworniczak, Juliane
Rossenbach, Christiana
Reisch, Simone
Hart, Christian
Fuzesi, Laszlo
Dockhorn-Dworniczak, Barbara
Dworniczak, Bernd
LABORATORY INVESTIGATION, 2015, 95 : 513A - 513A
[5] Detection of Mutant Circulating Tumor DNA (ctDNA) in Plasma of Patients With Colorectal Cancer (CRC)
Dworniczak, Juliane
Rossenbach, Christiana
Reisch, Simone
Hart, Christian
Fuzesi, Laszlo
Dockhorn-Dworniczak, Barbara
Dworniczak, Bernd
MODERN PATHOLOGY, 2015, 28 : 513A - 513A
[6] Prognostic value of circulating tumor DNA (ctDNA) detection during adjuvant chemotherapy in patients with stage III colorectal cancer: The interim report of a prospective, observational study
Peng, Junjie
Li, Yaqi
Mo, Shaobo
Ma, Xiaoji
Hu, Xiang
Zhang, Long
Huang, Dan
Cai, Sanjun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[7] Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).
Lee, Jeeyun
Kim, Hee C.
Kim, Seung Tae
He, Yupeng
Sample, Paul
Nakamura, Yoshiaki
Raymond, Victoria M.
Jaimovich, Ariel
Talasaz, AmirAli
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool
Tie, Jeanne
Wang, Yuxuan
Kinde, Isaac
Steel, Malcolm
Elsaleh, Hany
Singh, Madhu Sudan
Turner, Natalie Heather
Tran, Ben
Strausberg, Robert
Diaz, Luis A.
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[9] A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).
Tie, Jeanne
Cohen, Joshua
Wang, Yuxuan
Li, Lu
Lee, Margaret
Wong, Rachel
Kosmider, Suzanne
Wong, Hui-Li
Lee, Belinda
Burge, Matthew E.
Yip, Desmond
Karapetis, Christos Stelios
Price, Timothy Jay
Tebbutt, Niall C.
Haydon, Andrew Mark
Tomasetti, Cristian
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
Akagunduz, Baran
Guven, Deniz Can
Ozer, Muhammet
Okten, Ilker Nihat
Atag, Elif
Unek, Ilkay Tugba
Tatli, Ali Murat
Karaoglu, Aziz
JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)

← 1 2 3 4 5 →